Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Marpai, Inc. filings document material events, capital-structure matters and operating disclosures for a healthcare technology company whose Class A common stock trades on the OTCQX Market under MRAI. Recent Form 8-K reports cover results of operations, material definitive agreements and governance matters.
The filing record includes disclosures on promissory-note financing for working capital, amendments to note terms, officer appointments, and charter changes authorizing blank-check preferred stock. Marpai filings also identify its registered Class A common stock, emerging growth company status in certain reports, and formal risk and compliance references tied to its public-company reporting obligations.
Marpai, Inc. director Eitan Yaron received 75,000 restricted stock units (RSUs) that vested on a nine-month schedule and now beneficially owns 864,073 shares following the reported transactions. The RSUs vested in three tranches of 25,000 shares at three, six and nine months after grant, and the filing amends a prior Form 4 to correct the previously misstated post-transaction ownership total.
Marpai, Inc. director Eitan Yaron received 75,000 restricted stock units (RSUs) that vested on a nine-month schedule and now beneficially owns 864,073 shares following the reported transactions. The RSUs vested in three tranches of 25,000 shares at three, six and nine months after grant, and the filing amends a prior Form 4 to correct the previously misstated post-transaction ownership total.
Marpai, Inc. reported that on September 10, 2025, it entered into a Securities Purchase Agreement with three investors for a private sale of its Class A common stock. The company agreed to issue and sell 1,038,519 shares of common stock at $1.0592 per share.
The investor group includes HillCour Investment Fund, LLC, an entity controlled by Chief Executive Officer Damien Lamendola, which purchased 896,903 shares. The transaction was structured as a private placement relying on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. The shares have not been registered and may only be resold in the United States under a registration statement or a valid exemption.
Marpai, Inc. reported that on September 10, 2025, it entered into a Securities Purchase Agreement with three investors for a private sale of its Class A common stock. The company agreed to issue and sell 1,038,519 shares of common stock at $1.0592 per share.
The investor group includes HillCour Investment Fund, LLC, an entity controlled by Chief Executive Officer Damien Lamendola, which purchased 896,903 shares. The transaction was structured as a private placement relying on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. The shares have not been registered and may only be resold in the United States under a registration statement or a valid exemption.
Marpai, Inc. (MRAI) director Eitan Yaron acquired 75,000 restricted stock units (RSUs) on 08/19/2025 under a grant that vests in three equal tranches over nine months. The filing reports these RSUs were recorded at $0 price and, after the grant, Mr. Yaron beneficially owns 1,542,527 shares. The Form 4 indicates the reporting person is a director and the transaction was a non-derivative acquisition of Class A common stock RSUs.
Marpai, Inc. director Shiv Sagiv reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025, increasing his beneficial ownership to 135,000 shares of Class A common stock. The filing indicates the RSUs were granted under a plan with a nine-month vesting schedule: 25,000 RSUs vested at three months, 25,000 at six months, and 25,000 at nine months.
The Form 4 was signed on 09/15/2025 and notes the transaction was made pursuant to a plan intended to meet the Rule 10b5-1 affirmative defense. Sagiv is identified as a director. No options or derivative transactions are reported in this filing.
Marpai, Inc. director Shiv Sagiv reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025, increasing his beneficial ownership to 135,000 shares of Class A common stock. The filing indicates the RSUs were granted under a plan with a nine-month vesting schedule: 25,000 RSUs vested at three months, 25,000 at six months, and 25,000 at nine months.
The Form 4 was signed on 09/15/2025 and notes the transaction was made pursuant to a plan intended to meet the Rule 10b5-1 affirmative defense. Sagiv is identified as a director. No options or derivative transactions are reported in this filing.
Jennifer Calabrese, a director of Marpai, Inc. (MRAI), reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025. The Form 4 shows the 75,000 RSUs were acquired with a reported price of $0.00 and resulted in 125,000 shares of Class A common stock beneficially owned following the transaction. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions and that the RSUs vest over nine months in three equal tranches of 25,000 RSUs at three, six and nine months from the grant date.
The Form 4 was filed as an individual report and signed by Ms. Calabrese on 09/15/2025.
Jennifer Calabrese, a director of Marpai, Inc. (MRAI), reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025. The Form 4 shows the 75,000 RSUs were acquired with a reported price of $0.00 and resulted in 125,000 shares of Class A common stock beneficially owned following the transaction. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions and that the RSUs vest over nine months in three equal tranches of 25,000 RSUs at three, six and nine months from the grant date.
The Form 4 was filed as an individual report and signed by Ms. Calabrese on 09/15/2025.